ClinicalTrials.gg
CompletedNCT01107496Updated Oct 15, 2024Results posted

Evaluation of Immediate-Release Viloxazine in Adults With ADHD

A Phase 1/2 interventional study of IR Viloxazine and Placebo in Attention-Deficit/Hyperactivity Disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Supernus Pharmaceuticals, Inc..

Enrollment
18th of 22
52 · median 192
Started
2010
the only one that year
Phase 1/2
Only one
of the 22
Registered
2nd of 22
by date

Among the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., this one is the 18th largest by enrollment, is the only one that started in 2010, is the only one in phase 1/2, and was the 2nd registered.

Attention Deficit Disorder with Hyperactivity

1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a diagnosis of ADHD.

Read the detailed description

This will be a randomized, double-blind, multicenter, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years of age, inclusive, with a diagnosis of ADHD. Approximately 50 subjects will be enrolled at approximately 5 sites in the United States. Subjects will be randomized (1:1) to one of two treatment groups, immediate-release (IR) viloxazine or placebo. Primary objective is to determine the safety of IR viloxazine in adults with ADHD.

03

Conditions studied

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Keywords

  • ADHD
  • Adults
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide prior to any study procedure being conducted.
  2. Capable and willing to comply with study procedures.
  3. Male or female aged 18 to 64, inclusive.
  4. Subjects with a current diagnosis of ADHD as confirmed by the Conners' Adult ADHD Diagnostic Interview for (CAADID)
  5. Clinical Global Impression - Severity (CGI-S) score of 4 or higher.
  6. On no treatment for ADHD or willing to be withdrawn from an ongoing treatment after a of at least 10 days.
  7. (BMI) between 18.0 and 34.0 inclusive.
  8. Subject must be in general good health as determined by medical history, , and other analysis that, in the judgment of the Investigator, would confirm the Subject's good health.
  9. Females of (FOCP) who, if sexually active, agree to use acceptable forms of (including oral, transdermal, or implanted contraceptives; intrauterine device; female condom with spermicide; diaphragm with spermicide; cervical cap; abstinence; use of condom with spermicide by sexual partner or sterile [at least 6 months prior to SM administration] sexual partner) at least 14 days prior to start of study drug administration, throughout the study, and for 30 days following the last dose of SM.
  10. females with amenorrhea for at least 2 years or females who are permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).

Exclusion criteria

Exclusion Criteria

  1. Current or past history of psychotic disorder or major depressive disorder with psychotic features.
  2. Presence of another primary disorder.
  3. Suicidality, defined as either active suicidal plan/intent or active suicidal thoughts, in the 6 months before the Screening Visit or more than 1 lifetime suicide attempt. (The Columbia-Suicide Severity Rating Scales [C-SSRS] will be administered at each visit.)
  4. Substance or alcohol abuse/dependence within previous 6 months, or a positive urine drug screen at screening or baseline prior to first dose of study medication (SM).
  5. Any known or suspected significant medical or psychiatric illnesses that, in the judgment of the Investigator, may impair interpretation of study results or constitute a significant safety concern in the context of the clinical trial
  6. abnormalities ( according to Investigator's opinion) or vital sign abnormalities (systolic blood pressure [SBP] \<90 or >140 millimeters of mercury [mmHg], diastolic blood pressure [DBP] \<40 or >90mmHg, or heart rate [HR] \<40 or >100 beats per minute [BPM]) at screening.
  7. Clinically significant laboratory abnormalities; including presence of potential hepatic function impairment as shown by, but not limited to (ALT/SGPT) values >2 times (ULN), aspartate aminotransferase (AST/SGOT) > 2 times ULN, gamma-glutamyl transpeptidase (GGT) >3 times ULN, or total >1.5 ULN .
  8. Medications, including health food supplements judged by the Investigator to be likely to have central nervous system activity (for example, St John's Wort, gingko leaf, and melatonin), are not permitted during the study. If the subject is taking the medication prior to study entry, there must be a 7 day prior to first dose of SM.
  9. Lifetime history of tic disorder, Tourette's Disease, or organic brain disorder; or family history of Tourette's Disease.
  10. Current or lifetime history of hyperthyroidism unless treated and stable for at least 6 months.
  11. Participation in or plan to begin behavioral therapy during the study.
  12. Subject has a prior history of allergy or any significant adverse reaction (including rash) to study medication, or any of the product components.
  13. Females who are pregnant or lactating or are unwilling to use an acceptable form of throughout the study.
  14. Difficulty swallowing whole capsules.
  15. History of seizures or risk factors for seizures (e.g., head trauma), not including febrile seizures.
  16. Use of an drug or participation in an investigational study within 30 days prior to first dose of SM.
  17. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    IR Viloxazine

    Treatment A: immediate-release (IR) viloxazine capsules administered orally 3 times a day

    Drug: IR Viloxazine

  • Placebo comparator
    Placebo

    Treatment B: Placebo capsules administered orally 3 times a day

    Drug: Placebo

Interventions

  • DrugIR Viloxazine

    One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1. Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6.

    Also known as: immediate-release viloxazine, SPN-812V immediate-release

  • DrugPlacebo

    Placebo capsules administered orally 3 times a day

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events During 6 Weeks of Treatment

    The percent of subjects who took at least one dose of immediate-release viloxazine (Safety Population; N) and who reported at least one Adverse Event (n). The percent is calculated by dividing "the number of subjects who reported at least one Adverse Event (n)" by "the number of subjects in the Safety Population (N)" and multiplying the product by 100. The higher the percentage, the higher the incidence in the Safety Population

    Time frame: Weeks 1-6

Secondary outcomes

  1. Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 (End of Study)

    The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

    Time frame: Baseline and Week 6

  2. Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 1

    The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

    Time frame: Baseline and Week 1

  3. Change in Global Clinical Impression-Improvement (CGI-I) Score From Baseline Global Clinical Impression-Severity of Illness (CGI-S) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6

    The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The Clinical Global Impression-Severity of Illness (CGI-S) score is a single item clinician-rated assessment of the severity of subject's condition (symptoms) in relation to the clinician's total experience with patients with ADHD; it is rated on a 7-point scale with 1=Normal, not at all ill, 2=Borderline Ill, 3=Mildly Ill, 4=Moderately Ill, 5=Markedly Ill, 6=Severely Ill, 7=Among the most extremely ill patients. CGI-I scores at post-baseline visits were subtracted from CGI-S score at baseline; a change from baseline score \<0 represent better outcome.

    Time frame: Weeks 1, 2, 3, 4, 5, and 6

  4. Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 2, Week 3, Week 4, and Week 5

    The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

    Time frame: Baseline and Weeks 2, 3, 4, and 5

  5. Change From Baseline in the Self-rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6

    The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

    Time frame: Baseline and Week 6

  6. Global Clinical Impression-Improvement (CGI-I) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6

    The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. A CGI-I score \<4 represents a better outcome.

    Time frame: Weeks 1, 2, 3, 4, 5, and 6

07

Results

Posted Oct 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneIR ViloxazinePlacebo
Started2626
Dosed2625
Completed2424
Not completed22
Withdrew: Adverse event10
Withdrew: Lack of efficacy10
Withdrew: Protocol violation01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryIncidence of Adverse Events During 6 Weeks of Treatment

The percent of subjects who took at least one dose of immediate-release viloxazine (Safety Population; N) and who reported at least one Adverse Event (n). The percent is calculated by dividing "the number of subjects who reported at least one Adverse Event (n)" by "the number of subjects in the Safety Population (N)" and multiplying the product by 100. The higher the percentage, the higher the incidence in the Safety Population

Time frame:
Weeks 1-6
Reported as:
Number · percentage of subjects
Incidence of Adverse Events During 6 Weeks of Treatment
percentage of subjectsIR ViloxazinePlacebo
Incidence of Adverse Events During 6 Weeks of Treatment88.572.0
SecondaryChange From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 (End of Study)

The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

Time frame:
Baseline and Week 6
Reported as:
Median · units on a scale
Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 (End of Study)
units on a scaleIR ViloxazinePlacebo
Raw score; Baseline36.0 (20 to 54)35.0 (21 to 45)
Change from Baseline score; Week 6-11.5 (-38 to 4)-6.0 (-34 to 6)
Statistical analysis
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0414 · Median difference (net): 6.00 · 95% CI 1.00 to 12.00
SecondaryChange From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 1

The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

Time frame:
Baseline and Week 1
Reported as:
Median · units on a scale
Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 1
units on a scaleIR ViloxazinePlacebo
Raw score; Baseline36.0 (20 to 54)35.0 (21 to 45)
Change from Baseline score; Week 1-5.0 (-29 to 1)-2.0 (-25 to 7)
Statistical analysis
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0803 · Median difference (net): 3.00 · 95% CI 0.00 to 7.00
SecondaryChange in Global Clinical Impression-Improvement (CGI-I) Score From Baseline Global Clinical Impression-Severity of Illness (CGI-S) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6

The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The Clinical Global Impression-Severity of Illness (CGI-S) score is a single item clinician-rated assessment of the severity of subject's condition (symptoms) in relation to the clinician's total experience with patients with ADHD; it is rated on a 7-point scale with 1=Normal, not at all ill, 2=Borderline Ill, 3=Mildly Ill, 4=Moderately Ill, 5=Markedly Ill, 6=Severely Ill, 7=Among the most extremely ill patients. CGI-I scores at post-baseline visits were subtracted from CGI-S score at baseline; a change from baseline score \<0 represent better outcome.

Time frame:
Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Median · units on a scale
Change in Global Clinical Impression-Improvement (CGI-I) Score From Baseline Global Clinical Impression-Severity of Illness (CGI-S) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6
units on a scaleIR ViloxazinePlacebo
Change from "Baseline CGI-S Score"; Week 10.0 (-2 to 5)0.0 (-1 to 4)
Change from "Baseline CGI-S Score"; Week 2-1.0 (-2 to 5)0.0 (-2 to 4)
Change from "Baseline CGI-S Score"; Week 3-1.5 (-2 to 4)0.0 (-2 to 4)
Change from "Baseline CGI-S Score"; Week 4-1.5 (-3 to 4)0.0 (-2 to 5)
Change from "Baseline CGI-S Score"; Week 5-1.5 (-3 to 4)0.0 (-2 to 4)
Change from "Baseline CGI-S Score"; Week 6-1.0 (-3 to 4)0.0 (-1 to 4)
Statistical analysis
  • IR Viloxazine · Wilcoxon (Mann-Whitney) · p = 0.5308 · Median difference (net): 0.00 · 95% CI -1.00 to 1.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.2032 · Median difference (net): -1.00 · 95% CI -2.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0677 · Median difference (net): -1.00 · 95% CI -2.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0743 · Median difference (net): -1.00 · 95% CI -2.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0437 · Median difference (net): -1.00 · 95% CI -2.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1209 · Median difference (net): -1.00 · 95% CI -2.00 to 0.00
SecondaryChange From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 2, Week 3, Week 4, and Week 5

The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

Time frame:
Baseline and Weeks 2, 3, 4, and 5
Reported as:
Median · units on a scale
Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 2, Week 3, Week 4, and Week 5
units on a scaleIR ViloxazinePlacebo
Raw Score; Baseline36.0 (20 to 54)35.0 (21 to 45)
Change from Baseline score; Week 2-8.0 (-33 to 1)-6.0 (-27 to 6)
Change from Baseline score; Week 3-13.5 (-32 to -2)-6.0 (-34 to 5)
Change from Baseline score; Week 4-12.5 (-33 to -3)-7.0 (-31 to 5)
Change from Baseline score; Week 5-13.0 (-37 to 9)-7.0 (-32 to 7)
Statistical analysis
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.6022 · Median difference (net): 1.00 · 95% CI -4.00 to 6.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0794 · Median difference (net): -4.00 · 95% CI -10.0 to 1.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0747 · Median difference (net): -6.00 · 95% CI -10.0 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0545 · Median difference (net): -6.50 · 95% CI -12.0 to 0.00
SecondaryChange From Baseline in the Self-rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6

The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (\<0) represents a better outcome.

Time frame:
Baseline and Week 6
Reported as:
Median · units on a scale
Change From Baseline in the Self-rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6
units on a scaleIR ViloxazinePlacebo
Raw score; Baseline35.0 (7 to 49)34.0 (13 to 48)
Change from Baseline score; Week 6-10.5 (-46 to 7)-1.0 (-35 to 8)
Statistical analysis
  • IR Viloxazine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0349 · Median difference (net): 7.00 · 95% CI 1.00 to 13.00
SecondaryGlobal Clinical Impression-Improvement (CGI-I) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6

The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. A CGI-I score \<4 represents a better outcome.

Time frame:
Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Median · units on a scale
Global Clinical Impression-Improvement (CGI-I) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6
units on a scaleIR ViloxazinePlacebo
Week 15.0 (3 to 7)5.0 (3 to 6)
Week 24.0 (3 to 6)5.0 (2 to 6)
Week 33.5 (3 to 5)5.0 (2 to 6)
Week 44.0 (2 to 5)5.0 (2 to 6)
Week 54.0 (2 to 5)5.0 (2 to 6)
Week 63.5 (2 to 5)5.0 (2 to 6)
Statistical analysis
  • IR Viloxazine vs Placebo · Wilcoxon rank-sum test · p = 0.4038 · Median difference (net): -0.50 · 95% CI -1.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon rank-sum test · p = 0.4460 · Median difference (net): -0.50 · 95% CI -1.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon rank-sum test · p = 0.0549 · Median difference (net): -0.50 · 95% CI -1.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon rank-sum test · p = 0.0759 · Median difference (net): -0.50 · 95% CI -1.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon rank-sum test · p = 0.0342 · Median difference (net): -0.50 · 95% CI -1.00 to 0.00
  • IR Viloxazine vs Placebo · Wilcoxon rank-sum test · p = 0.0474 · Median difference (net): -1.00

Adverse events

Collected over Weeks 1-6 of Treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IR Viloxazine0/26 (0%)0/26 (0%)23/26 (88.5%)
Placebo0/25 (0%)0/25 (0%)18/25 (72%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventIR ViloxazinePlacebo
NauseaGastrointestinal disorders10/262/25
HeadacheNervous system disorders8/269/25
Decreased appetiteMetabolism and nutrition disorders8/261/25
InsomniaPsychiatric disorders8/261/25
Dry mouthGastrointestinal disorders6/263/25
NasopharyngitisInfections and infestations0/264/25
ConstipationGastrointestinal disorders3/262/25
DyspepsiaGastrointestinal disorders3/260/25
FatigueGeneral disorders3/261/25
IrritabilityGeneral disorders3/261/25

Baseline characteristics

Safety Population, defined as subjects who were randomly assigned to one of two treatment groups and took at least one dose of study medication

Age, Continuous
Age, Continuous(years)IR ViloxazinePlaceboTotal
Mean37.7 ± 14.0443.1 ± 10.3940.4 ± 12.56
Sex: Female, Male
Sex: Female, Male(Participants)IR ViloxazinePlaceboTotal
Female14923
Male121628
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IR ViloxazinePlaceboTotal
White242448
Asian011
Other202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IR ViloxazinePlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino252550
Height
Height(inches)IR ViloxazinePlaceboTotal
Mean66.740 ± 3.510368.406 ± 4.085167.557 ± 3.8573
Weight
Weight(pounds (lbs))IR ViloxazinePlaceboTotal
Mean163.85 ± 33.641171.05 ± 33.057167.38 ± 33.221
BMI
BMI(kilograms per square meter)IR ViloxazinePlaceboTotal
Mean25.688 ± 3.721625.664 ± 4.362025.676 ± 4.0073
08

Study locations

4 sites
  • Bradenton, Florida 34208, United States
  • Libertyville, Illinois 60048, United States
  • Owensboro, Kentucky 42301, United States
  • Herndon, Virginia 20170, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2024, 13 years 10 months after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2010
First posted
Apr 21, 2010
Start
Jun 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results delay requested
Dec 17, 2012
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01107496
Responsible party
Sponsor
First posted
Apr 21, 2010
Start date
Jun 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Study contacts

Jonathan Rubin, MD
study director · Supernus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion